Orthocell (ASX:OCC) reported that its Remplir nerve repair device has been successfully used in 23 surgeries on injured Ukrainian soldiers, following a humanitarian delivery in April 2025, according to a Wednesday Australian bourse filing.

The device was used in both primary and secondary nerve repairs, with surgeons reporting positive feedback on its portability, ease of use, and suitability for major trauma in defense settings, per the filing.

The company plans to continue monitoring patient outcomes and collecting clinical data to support future engagement with defense organizations globally, the filing added.

The company's shares rose 2% in recent Wednesday trade.